2m 2m 2m 2m 2m 2m 2m
CV Sciences (CVSI)
OTC
$0.03-$0.001 (-4.44%)
Price as of Jun 03, 2026- $5.6MMarket Cap
- 8.81%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
CV Sciences (CVSI)
$0.03-$0.001 (-4.44%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 13.8M -12.20% | 15.7M -1.87% | 16.0M -1.24% | 16.2M -19.17% | |
Cost of Revenue | 7.0M -17.57% | 8.5M -4.28% | 8.9M -16.29% | 10.7M -6.80% | |
Gross Profit | 6.8M -5.80% | 7.2M +1.17% | 7.1M +27.66% | 5.5M -35.58% | |
Sales and Marketing Expense | 7.6M -17.51% | 9.2M -5.18% | 9.7M +712.08% | 1.2M -7.69% | |
Research and Development Expense | -122,000 +3.39% | -118,000 -21.85% | -151,000 -50.81% | -307,000 -74.09% | |
Depreciation and Amortization Expense | 192,000 -42.51% | 334,000 +42.13% | 235,000 -76.31% | 992,000 -13.96% | |
Total Operating Expenses | 7.6M -17.51% | 9.2M -5.18% | 9.7M -21.39% | 12.4M -54.19% | |
Operating Profit | -470,000 -78.54% | -2.2M -165.18% | 3.4M +149.07% | -6.8M -62.88% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -600,000 -61.06% | -1.5M +1,000.71% | |
Interest Income and Expense and Net | 0 N/A | 0 +100.00% | -600,000 -61.06% | -1.5M +1,000.71% | |
Total Nonoperating Income and Expense | -479,000 +125.94% | -212,000 -19.70% | -264,000 -82.87% | -1.5M +1,000.71% | |
Income before Taxes | -949,000 -60.49% | -2.4M -177.58% | 3.1M +137.48% | -8.3M -47.18% | |
Income Taxes | 9,000 +212.50% | -8,000 +33.33% | -6,000 -87.23% | -47,000 -45.98% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -958,000 -59.98% | -2.4M -177.18% | 3.1M +137.76% | -8.2M -47.19% | |
Net Income from Continuing Operations Applicable to Common | -949,000 -60.49% | -2.4M -177.43% | 3.1M +133.96% | -9.1M -41.60% | |
Basic EPS and Net Income | -0.01 0.00% | -0.01 -150.00% | 0.02 +128.57% | -0.07 -50.00% | |
Diluted EPS and Net Income | -0.01 0.00% | -0.01 -150.00% | 0.02 +128.57% | -0.07 -50.00% | |
Basic Weighted Average Shares | 184.3M +4.94% | 175.6M +14.05% | 154.0M +11.53% | 138.0M +28.03% | |
Diluted Weighted Average Shares | 184.3M +4.94% | 175.6M +14.05% | 154.0M +11.53% | 138.0M +28.03% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 278,000 -38.77% | 454,000 -65.53% | 1.3M +115.55% | 611,000 -55.56% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 278,000 -38.77% | 454,000 -65.53% | 1.3M +115.55% | 611,000 -55.56% | |
Total Current Assets | 5.1M -17.78% | 6.2M -21.35% | 7.9M -28.68% | 11.1M -21.54% | |
Accumulated Depreciation | 1.5M +12.54% | 1.4M +29.78% | 1.1M +28.64% | 817,000 -76.88% | |
Property and Plant and Equipment and Net | 344,000 -13.78% | 399,000 +5.28% | 379,000 -34.09% | 575,000 -66.51% | |
Total Long-Term Assets | 47,000 -62.99% | 127,000 -57.09% | 296,000 -41.39% | 505,000 -25.52% | |
Total Assets | 7.0M -12.17% | 7.9M -13.84% | 9.2M -27.76% | 12.7M -29.50% | |
Income Taxes Payable | 7,000 +75.00% | 4,000 -78.95% | 19,000 +72.73% | 11,000 -82.26% | |
Total Short-Term Debt | 1.3M N/A | N/A N/A | N/A N/A | 0 -100.00% | |
Total Current Liabilities | 5.0M -18.15% | 6.1M -0.10% | 6.1M -54.07% | 13.3M -7.93% | |
Total Long-Term Debt | 387,000 +287.00% | 100,000 -97.53% | 4.0M +5.20% | 3.8M +109.99% | |
Total Long-Term Liabilities | 501,000 N/A | 0 -100.00% | 105,000 -50.00% | 210,000 +69.35% | |
Total Liabilities | 5.5M -10.40% | 6.1M -2.62% | 6.3M -53.40% | 13.5M -6.95% | |
Retained Earnings | -87.9M +1.10% | -87.0M +2.83% | -84.6M -3.54% | -87.7M +10.34% | |
Total Stockholders Equity | 1.5M -18.22% | 1.8M -38.17% | 2.9M +473.62% | -777,000 -121.93% | |
Total Shares Outstanding | 184.3M 0.00% | 184.3M +13.97% | 161.7M +6.29% | 152.1M +35.23% | |
Cash Flow | |||||
Cash from Operating Activities | -407,000 -52.73% | -861,000 -138.22% | 2.3M +219.52% | -1.9M -74.82% | |
Capital Expenditures | 109,000 +505.56% | 18,000 N/A | N/A N/A | 0 -100.00% | |
Cash from Investing Activities | -109,000 +289.29% | -28,000 -82.05% | -156,000 N/A | 0 +100.00% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 337,000 +953.13% | 32,000 +102.30% | -1.4M -224.09% | 1.1M -74.35% | |
Financials Ratio | |||||
Gross Margin | 48.97% +7.29% | 45.64% +3.10% | 44.27% +29.26% | 34.25% -20.31% | |
Operating Margin | -3.41% -75.56% | -13.94% -166.42% | 20.99% +149.69% | -42.25% -54.08% | |
Return on Assets | -12.87% -53.97% | -27.96% -198.85% | 28.28% +153.03% | -53.33% -16.52% | |
Return on Equity | -58.72% -42.38% | -101.92% -134.92% | 291.82% +149.13% | -593.93% +181.71% | |
Revenue Growth | -12.20% +552.99% | -1.87% +50.62% | -1.24% -93.53% | -19.17% +6.89% | |
Current Ratio | 1.03 +0.46% | 1.02 -21.28% | 1.30 +55.28% | 0.84 -14.78% | |
Cash Ratio | 0.06 -25.17% | 0.07 -65.51% | 0.22 +369.28% | 0.05 -51.74% | |
Debt-to-Equity Ratio | 1.12 N/A | N/A N/A | N/A N/A | -4.95 -817.69% | |
Debt-to-Assets Ratio | 0.24 N/A | N/A N/A | N/A N/A | 0.30 +123.30% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow